Brian Casey[email protected]HomeWeek in Review: Google's medical imaging play | TVUS to check IUDs | Following up findingsOctober 7, 2022HomeWeek in Review: Meet the Minnies finalists | What worries rad admins | What next for AI?September 30, 2022Digital X-RayPresident of Ohio portable x-ray firm gets 15-year prison termThe president of a portable x-ray firm in Ohio has been sentenced to 15 years in prison for a scheme in which he defrauded the Medicare and Medicaid system of $2 million for services the company did not provide.September 29, 2022EconomicsRadiology admins worry about staff costs in new MICI numbersRadiology administrators are struggling to cope with rising staff costs and personnel shortages as they also try to manage a variety of financial pressures, according to the latest numbers from the Medical Imaging Confidence Index (MICI).September 25, 2022Image ProcessingWeek in Review: 4D ultrasound revelations | RTs on the night shift | New MRI contrastSeptember 23, 2022MRIBracco prepares launch of its version of gadopiclenol MRI contrastContrast agent developer Bracco is preparing for a commercial launch of its version of gadopiclenol, the new MRI gadolinium-based contrast agent that has received approval in the U.S. Bracco will sell the agent as Vueway.September 20, 2022MRIGuerbet gets FDA approval for Elucirem lower-dose MRI contrastContrast agent developer Guerbet has received approval from the U.S. Food and Drug Administration (FDA) for Elucirem (gadopiclenol), a new MRI contrast agent the company is developing in collaboration with Bracco.September 20, 2022HomeWeek in Review: PET of Alzheimer's | News from ISCT | Osteoporosis webinarSeptember 16, 2022HomeWeek in Review: Race adjustment in x-ray | AI + photon-counting CT | Attitudes toward AISeptember 9, 2022HomeWeek in Review: Meet the Minnies candidates | Imaging's unseen side | AI of x-raySeptember 2, 2022Page 1 of 140Next PageTop StoriesMolecular ImagingSNMMI: Retreatment with Lu-177 PSMA-617 shows promise in mCRPC patientsRetreatment with Lu-177 PSMA-617 is emerging as a potential approach in men with prostate cancer.Nuclear MedicineSNMMI: New PET tracers developed for imaging brain disordersMolecular ImagingSNMMI: SPECT/CT valuable after Lu-177 therapyWomens ImagingDL model improves detection of breast arterial calcificationsSponsor ContentJoin Us June 26 at 12 Noon ET for a FREE webinar!
